Literature DB >> 11510716

Combination of cervical interleukin-6 and -8, phosphorylated insulin-like growth factor-binding protein-1 and transvaginal cervical ultrasonography in assessment of the risk of preterm birth.

M Kurkinen-Räty1, A Ruokonen, S Vuopala, M Koskela, E M Rutanen, T Kärkkäinen, P Jouppila.   

Abstract

OBJECTIVE: To determine the value of combinations of cervical interleukin-6 (IL-6), cervical interleukin-8 (IL-8), the phosphorylated isoform of insulin-like growth-factor binding protein-1 (IGFBP-1), and cervical ultrasonography in the prediction of preterm birth.
DESIGN: Prospective follow up.
SETTING: Oulu University Hospital maternity clinic from February 1997 to July 1998. POPULATION: Women with singleton pregnancies (n = 77), referred from outpatient clinics at 22-32 weeks of gestation with symptoms (uterine contractions) or signs (cervical change) of threatened preterm birth. Symptomless women (n = 78) matched for gestational age, parity and maternal age at recruitment were studied as a reference group.
METHODS: A urine sample for bacterial culture was collected, and cervical swab samples for assays of interleukin-6 and -8 and phoshorylated IGFBP-1 were taken before digital cervical examination. A Pap smear for analysis of bacterial vaginosis and samples for analysis of chlamydia and streptococci were also obtained. Cervical measurements were made by transvaginal ultrasonography. The same sampling and cervical measurement were repeated twice at two-week intervals. The cutoff values of the markers were determined by receiver-operating characteristic curve analysis. MAIN OUTCOME MEASURE: Preterm birth (<37 weeks).
RESULTS: The preterm birth (<37 weeks) rate for women in the study group was 16% (12/77). The cervical interleukin-6 cutoff value (61 ng/L) at first visit had a sensitivity of 73% and a specificity of 61% in predicting preterm birth, with a positive likelihood ratio (LR+ ) of 1.9 (95% CI 1.2-3.0). An ultrasonographically measured cervical index value of > 0.36 at recruitment predicted preterm birth in 25% (5/20) of the study group compared with 9% (5/54); LR+ 2.2 (95% CI 1.03-4.7). Cervical phosphorylated IGFBP-1 > 6.4 microg/L [LR+ 1.8 (95% CI 0.7-2.9)], interleukin-8 > 3739 ng/L [LR+ 1.4 (95% CI 0.9-2.4)], and ultrasonograpic cervical length < 29.3 mm [LR+ 2.7 (95% CI 0.8-9.7)] increased the risk of preterm birth. According to the logistic regression model, a combination of IL-6, and IL-8 and cervical index increased the specificity to 97%, but the sensitivity fell to 30% in detecting preterm birth. There was a significantly increased incidence of puerperal infections if phosphorylated IGFBP-1 concentrations were elevated (> 21.0 microg/L), 36% (4/11) compared with 4.6% (3/65), LR+ 6.7 (95% CI 2.7-17), the sensitivity being 67% (4/6) and the specificity 90% (63/70). Elevated phosphorylated IGFBP-1 concentrations (> 21.6 microg/L) were also associated with an increased risk of neonatal infections; LR+ 8.0 (95% CI 3.5-18).
CONCLUSIONS: An increase in cervical IL-6 concentration and the ultrasonographically measured cervical index appear to be associated with preterm birth. A combination of these markers with measurement of cervical IL-8 appears to be the best predictor of preterm birth. Neither the sensitivity nor specificity of the tests used in this study are good enough to predict preterm birth for clinical decision making. Cervical phosphorylated IGFBP-1 seems to be a marker of puerperal and neonatal infectious morbidity in cases of threatened preterm delivery, suggesting early tissue degradation at the choriodecidual interface.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510716     DOI: 10.1111/j.1471-0528.2001.00199.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

1.  A high concentration of fetal fibronectin in cervical secretions increases the risk of intra-amniotic infection and inflammation in patients with preterm labor and intact membranes.

Authors:  Kyung Joon Oh; Roberto Romero; Jee Yoon Park; Jihyun Kang; Joon-Seok Hong; Bo Hyun Yoon
Journal:  J Perinat Med       Date:  2019-04-24       Impact factor: 1.901

Review 2.  Cervical phosphorylated insulin-like growth factor binding protein-1 test for the prediction of preterm birth: a systematic review and metaanalysis.

Authors:  Agustin Conde-Agudelo; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2015-07-03       Impact factor: 8.661

3.  Serum inflammatory mediators in pregnancy: changes after periodontal treatment and association with pregnancy outcomes.

Authors:  Bryan S Michalowicz; M John Novak; James S Hodges; Anthony DiAngelis; William Buchanan; Panos N Papapanou; Dennis A Mitchell; James E Ferguson; Virginia Lupo; James Bofill; Stephen Matseoane; Michelle Steffen; Jeffrey L Ebersole
Journal:  J Periodontol       Date:  2009-11       Impact factor: 6.993

4.  Does Assessment of Cervical Phosphorylated Insulin-like Growth Factor Binding Protein-1 by Bedside Vaginal Swab Test Really Predict Preterm Birth?

Authors:  Laura Tenoudji-Cohen Couka; Xavier-Côme Donato; Eric Glowaczower; Anne Squercioni-Aumont; Maria Katsogiannou; Raoul Desbriere
Journal:  Reprod Sci       Date:  2021-01-06       Impact factor: 3.060

5.  Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract.

Authors:  Geert Zegels; Geert Aa Van Raemdonck; Wiebren Aa Tjalma; Xaveer Wm Van Ostade
Journal:  Proteome Sci       Date:  2010-12-08       Impact factor: 2.480

6.  Can preterm labour be predicted in low risk pregnancies? Role of clinical, sonographic, and biochemical markers.

Authors:  Reva Tripathi; Shakun Tyagi; Nilanchali Singh; Yedla Manikya Mala; Chanchal Singh; Preena Bhalla; Siddhartha Ramji
Journal:  J Pregnancy       Date:  2014-10-22

7.  Performance of cervical phIGFBP-1 test alone or combined with short cervical length to predict spontaneous preterm birth in symptomatic women.

Authors:  Florent Fuchs; Marie Houllier; Soizic Leparco; Anne Guyot; Marie-Victoire Senat; Hervé Fernandez
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.